JP2022502055A5 - - Google Patents
Info
- Publication number
- JP2022502055A5 JP2022502055A5 JP2021517350A JP2021517350A JP2022502055A5 JP 2022502055 A5 JP2022502055 A5 JP 2022502055A5 JP 2021517350 A JP2021517350 A JP 2021517350A JP 2021517350 A JP2021517350 A JP 2021517350A JP 2022502055 A5 JP2022502055 A5 JP 2022502055A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- guide
- composition
- seq
- rna
- Prior art date
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862738956P | 2018-09-28 | 2018-09-28 | |
| US62/738,956 | 2018-09-28 | ||
| US201962834334P | 2019-04-15 | 2019-04-15 | |
| US62/834,334 | 2019-04-15 | ||
| US201962841740P | 2019-05-01 | 2019-05-01 | |
| US62/841,740 | 2019-05-01 | ||
| PCT/US2019/053423 WO2020069296A1 (en) | 2018-09-28 | 2019-09-27 | Compositions and methods for lactate dehydrogenase (ldha) gene editing |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022502055A JP2022502055A (ja) | 2022-01-11 |
| JP2022502055A5 true JP2022502055A5 (https=) | 2022-09-30 |
| JPWO2020069296A5 JPWO2020069296A5 (https=) | 2022-09-30 |
Family
ID=68296656
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021517350A Pending JP2022502055A (ja) | 2018-09-28 | 2019-09-27 | 乳酸デヒドロゲナーゼ（ｌｄｈａ）遺伝子編集のための組成物及び方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20210222173A1 (https=) |
| EP (1) | EP3856901A1 (https=) |
| JP (1) | JP2022502055A (https=) |
| KR (1) | KR20210086621A (https=) |
| CN (1) | CN113056559A (https=) |
| AU (1) | AU2019347517A1 (https=) |
| BR (1) | BR112021005718A2 (https=) |
| CA (1) | CA3114425A1 (https=) |
| CO (1) | CO2021005231A2 (https=) |
| IL (1) | IL281529A (https=) |
| MX (1) | MX2021003457A (https=) |
| PH (1) | PH12021550686A1 (https=) |
| SG (1) | SG11202102660RA (https=) |
| TW (1) | TW202028460A (https=) |
| WO (1) | WO2020069296A1 (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3946598A1 (en) * | 2019-03-28 | 2022-02-09 | Intellia Therapeutics, Inc. | Compositions and methods comprising a ttr guide rna and a polynucleotide encoding an rna-guided dna binding agent |
| JP2023546175A (ja) | 2020-10-14 | 2023-11-01 | ジョージ・メイソン・リサーチ・ファウンデーション・インコーポレイテッド | 脂質ナノ粒子製造の方法及びそれに由来する組成物 |
| WO2022256655A2 (en) * | 2021-06-04 | 2022-12-08 | Arbor Biotechnologies, Inc. | Gene editing systems comprising an rna guide targeting lactate dehydrogenase a (ldha) and uses thereof |
| EP4423271A2 (en) | 2021-10-28 | 2024-09-04 | Regeneron Pharmaceuticals, Inc. | Crispr/cas-related methods and compositions for knocking out c5 |
| WO2023122433A1 (en) * | 2021-12-22 | 2023-06-29 | Arbor Biotechnologies, Inc. | Gene editing systems targeting hydroxyacid oxidase 1 (hao1) and lactate dehydrogenase a (ldha) |
| EP4473103A2 (en) | 2022-02-02 | 2024-12-11 | Regeneron Pharmaceuticals, Inc. | Anti-tfr:gaa and anti-cd63:gaa insertions for treatment of pompe disease |
| CN114657181B (zh) * | 2022-04-01 | 2023-08-25 | 安徽大学 | 一种靶向H1.4的sgRNA以及H1.4基因编辑方法 |
| WO2023212677A2 (en) | 2022-04-29 | 2023-11-02 | Regeneron Pharmaceuticals, Inc. | Identification of tissue-specific extragenic safe harbors for gene therapy approaches |
| WO2023235725A2 (en) | 2022-05-31 | 2023-12-07 | Regeneron Pharmaceuticals, Inc. | Crispr-based therapeutics for c9orf72 repeat expansion disease |
| CN119421951A (zh) | 2022-05-31 | 2025-02-11 | 瑞泽恩制药公司 | 用于c9orf72重复序列扩增疾病的crispr干扰疗法 |
| IL318625A (en) | 2022-07-29 | 2025-03-01 | Regeneron Pharma | Compositions and methods for transferrin receptor (TFR)-mediated delivery to brain and muscle |
| CN120265314A (zh) | 2022-09-28 | 2025-07-04 | 瑞泽恩制药公司 | 抗体抗性修饰受体以增强基于细胞的疗法 |
| IL320016A (en) | 2022-11-04 | 2025-06-01 | Regeneron Pharma | Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle |
| AU2023379457A1 (en) | 2022-11-14 | 2025-05-15 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes |
| US20250049896A1 (en) | 2023-07-28 | 2025-02-13 | Regeneron Pharmaceuticals, Inc. | Anti-tfr:acid sphingomyelinase for treatment of acid sphingomyelinase deficiency |
| AU2024315073A1 (en) | 2023-07-28 | 2026-01-22 | Regeneron Pharmaceuticals, Inc. | Use of bgh-sv40l tandem polya to enhance transgene expression during unidirectional gene insertion |
| AU2024317483A1 (en) | 2023-07-28 | 2026-01-29 | Regeneron Pharmaceuticals, Inc. | Anti-tfr:gaa and anti-cd63:gaa insertion for treatment of pompe disease |
| WO2025049524A1 (en) | 2023-08-28 | 2025-03-06 | Regeneron Pharmaceuticals, Inc. | Cxcr4 antibody-resistant modified receptors |
| CN121752723A (zh) * | 2023-08-31 | 2026-03-27 | 正基基因科技有限公司 | 编码crispr相关蛋白的核酸及其应用 |
| AU2024335327A1 (en) | 2023-09-01 | 2026-03-26 | Renagade Therapeutics Management Inc. | Gene editing systems, compositions, and methods for treatment of vexas syndrome |
| WO2025128871A2 (en) | 2023-12-13 | 2025-06-19 | Renagade Therapeutics Management Inc. | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents |
| WO2025162435A1 (en) * | 2024-02-02 | 2025-08-07 | Accuredit Therapeutics (Suzhou) Co., Ltd. | Compositions and methods for treatment of liver disease |
| WO2025174765A1 (en) | 2024-02-12 | 2025-08-21 | Renagade Therapeutics Management Inc. | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents |
| WO2025184567A1 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response |
| WO2025235388A1 (en) | 2024-05-06 | 2025-11-13 | Regeneron Pharmaceuticals, Inc. | Transgene genomic identification by nuclease-mediated long read sequencing |
| WO2025265017A1 (en) | 2024-06-20 | 2025-12-26 | Regeneron Pharmaceuticals, Inc. | Ass1 gene insertion for the treatment of citrullinemia type i |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5585481A (en) | 1987-09-21 | 1996-12-17 | Gen-Probe Incorporated | Linking reagents for nucleotide probes |
| US5378825A (en) | 1990-07-27 | 1995-01-03 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs |
| KR940703846A (ko) | 1991-12-24 | 1994-12-12 | 비. 린네 파샬 | 갭(gap)이 형성된 2′ 변성된 올리고뉴클레오티드(gapped 2′ modifed oligonucleotides) |
| US6169169B1 (en) | 1994-05-19 | 2001-01-02 | Dako A/S | PNA probes for detection of Neisseria gonorrhoeae and Chlamydia trachomatis |
| DK2931898T3 (en) | 2012-12-12 | 2016-06-20 | Massachusetts Inst Technology | CONSTRUCTION AND OPTIMIZATION OF SYSTEMS, PROCEDURES AND COMPOSITIONS FOR SEQUENCE MANIPULATION WITH FUNCTIONAL DOMAINS |
| WO2014093694A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes |
| CA2895155C (en) | 2012-12-17 | 2021-07-06 | President And Fellows Of Harvard College | Rna-guided human genome engineering |
| US20150165054A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting caspase-9 point mutations |
| US20150376586A1 (en) | 2014-06-25 | 2015-12-31 | Caribou Biosciences, Inc. | RNA Modification to Engineer Cas9 Activity |
| EP3169309B1 (en) | 2014-07-16 | 2023-05-10 | Novartis AG | Method of encapsulating a nucleic acid in a lipid nanoparticle host |
| AU2015330670B2 (en) * | 2014-10-10 | 2022-01-06 | Novo Nordisk Health Care Ag | Therapeutic inhibition of lactate dehydrogenase and agents therefor |
| EP3265559B1 (en) | 2015-03-03 | 2021-01-06 | The General Hospital Corporation | Engineered crispr-cas9 nucleases with altered pam specificity |
| US11845933B2 (en) | 2016-02-03 | 2023-12-19 | Massachusetts Institute Of Technology | Structure-guided chemical modification of guide RNA and its applications |
| TWI773666B (zh) | 2016-03-30 | 2022-08-11 | 美商英特利亞醫療公司 | Crispr/cas 組分之脂質奈米粒子調配物 |
| EP3452080A4 (en) * | 2016-05-02 | 2019-10-09 | The Regents of the University of California | MAMMALIAN CELLS WITHOUT LACTATE DEHYDROGENASE ACTIVITY |
| AU2017374044B2 (en) | 2016-12-08 | 2023-11-30 | Intellia Therapeutics, Inc. | Modified guide RNAs |
-
2019
- 2019-09-27 BR BR112021005718-8A patent/BR112021005718A2/pt not_active IP Right Cessation
- 2019-09-27 EP EP19790921.1A patent/EP3856901A1/en active Pending
- 2019-09-27 CA CA3114425A patent/CA3114425A1/en active Pending
- 2019-09-27 SG SG11202102660RA patent/SG11202102660RA/en unknown
- 2019-09-27 TW TW108135340A patent/TW202028460A/zh unknown
- 2019-09-27 WO PCT/US2019/053423 patent/WO2020069296A1/en not_active Ceased
- 2019-09-27 CN CN201980076179.XA patent/CN113056559A/zh active Pending
- 2019-09-27 AU AU2019347517A patent/AU2019347517A1/en not_active Withdrawn
- 2019-09-27 JP JP2021517350A patent/JP2022502055A/ja active Pending
- 2019-09-27 MX MX2021003457A patent/MX2021003457A/es unknown
- 2019-09-27 KR KR1020217012025A patent/KR20210086621A/ko not_active Withdrawn
-
2021
- 2021-03-16 IL IL281529A patent/IL281529A/en unknown
- 2021-03-25 US US17/212,901 patent/US20210222173A1/en not_active Abandoned
- 2021-03-26 PH PH12021550686A patent/PH12021550686A1/en unknown
- 2021-04-23 CO CONC2021/0005231A patent/CO2021005231A2/es unknown
-
2025
- 2025-05-16 US US19/210,426 patent/US20260035697A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022502055A5 (https=) | ||
| JP2021531804A5 (https=) | ||
| JPWO2020069296A5 (https=) | ||
| JP7625555B2 (ja) | 修飾されたガイドｒｎａ | |
| JP6799058B2 (ja) | アレル選択的な遺伝子編集およびその使用 | |
| US5744460A (en) | Combination for treatment of proliferative diseases | |
| JP2024099745A5 (https=) | ||
| JP2021526804A5 (https=) | ||
| JP2016520312A5 (https=) | ||
| JP2018536689A5 (https=) | ||
| JP2017532038A5 (https=) | ||
| CN1471408A (zh) | 运用bcl-2反义寡聚体治疗bcl-2疾病的方法 | |
| IL277970B2 (en) | Oligomeric compounds comprising modified oligonucleotides and conjugated groups for use in the treatment of end-stage renal disease, chronic kidney disease and coronary artery disease | |
| JP2019512543A (ja) | β−カテニン関連疾患又は障害の治療のための組成物及び方法 | |
| JP2013504603A5 (https=) | ||
| JPWO2020205473A5 (https=) | ||
| JP2002512792A (ja) | インスリン様増殖因子ｉｉアンチセンスオリゴヌクレオチド配列および細胞増殖を調節するためのその使用方法 | |
| JPWO2020028327A5 (https=) | ||
| JP5406024B2 (ja) | Ｂｃｌ−ＸＬ特異的ｓｉＮＡを用いる癌治療法 | |
| TW201038278A (en) | Rnai molecule for thymidylate synthase and use thereof | |
| JP6437930B2 (ja) | 悪性胸膜中皮腫を治療するためのマイクロｒｎａを基にしたアプローチ | |
| JP2005531624A (ja) | 脈管組織または血管の過形成に関連する疾患または障害の予防または治療方法 | |
| JP7514563B2 (ja) | オルガノイドおよび抗炎症剤を含む炎症性腸疾患の予防または治療用薬学組成物 | |
| JP2026504743A (ja) | 膵管腺癌に対するｅｇｆｒ、ｒａｆ１、およびｓｔａｔ３を阻害する三剤併用療法 | |
| WO2020099525A2 (en) | Oligonucleotides influencing the regulation of the fatty acid metabolism |